全文获取类型
收费全文 | 164780篇 |
免费 | 12245篇 |
国内免费 | 6235篇 |
专业分类
耳鼻咽喉 | 1293篇 |
儿科学 | 3067篇 |
妇产科学 | 2523篇 |
基础医学 | 31167篇 |
口腔科学 | 3252篇 |
临床医学 | 12039篇 |
内科学 | 25489篇 |
皮肤病学 | 2721篇 |
神经病学 | 13238篇 |
特种医学 | 2797篇 |
外国民族医学 | 29篇 |
外科学 | 11073篇 |
综合类 | 23097篇 |
现状与发展 | 31篇 |
预防医学 | 10416篇 |
眼科学 | 1890篇 |
药学 | 22374篇 |
15篇 | |
中国医学 | 5098篇 |
肿瘤学 | 11651篇 |
出版年
2024年 | 334篇 |
2023年 | 2170篇 |
2022年 | 4901篇 |
2021年 | 5877篇 |
2020年 | 4857篇 |
2019年 | 4823篇 |
2018年 | 4929篇 |
2017年 | 5231篇 |
2016年 | 5255篇 |
2015年 | 6044篇 |
2014年 | 9652篇 |
2013年 | 10977篇 |
2012年 | 9927篇 |
2011年 | 11480篇 |
2010年 | 9054篇 |
2009年 | 8967篇 |
2008年 | 8932篇 |
2007年 | 8434篇 |
2006年 | 7567篇 |
2005年 | 6697篇 |
2004年 | 5801篇 |
2003年 | 4966篇 |
2002年 | 3791篇 |
2001年 | 3243篇 |
2000年 | 2953篇 |
1999年 | 2556篇 |
1998年 | 2440篇 |
1997年 | 2226篇 |
1996年 | 1984篇 |
1995年 | 1828篇 |
1994年 | 1688篇 |
1993年 | 1429篇 |
1992年 | 1261篇 |
1991年 | 1143篇 |
1990年 | 1005篇 |
1989年 | 841篇 |
1988年 | 735篇 |
1987年 | 684篇 |
1986年 | 615篇 |
1985年 | 958篇 |
1984年 | 958篇 |
1983年 | 611篇 |
1982年 | 664篇 |
1981年 | 553篇 |
1980年 | 491篇 |
1979年 | 375篇 |
1978年 | 295篇 |
1977年 | 255篇 |
1976年 | 250篇 |
1975年 | 170篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Primary cutaneous anaplastic large cell lymphomas with 6p25.3 rearrangement exhibit particular histological features
下载免费PDF全文
![点击此处可从《Histopathology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
32.
33.
JeongYun Choi Haeseung Lee EunJi Kwon HyeonJoon Kong OkSeon Kwon HyukJin Cha 《Molecular oncology》2021,15(2):679
The acquisition of chemoresistance remains a major cause of cancer mortality due to the limited accessibility of targeted or immune therapies. However, given that severe alterations of molecular features during epithelial‐to‐mesenchymal transition (EMT) lead to acquired chemoresistance, emerging studies have focused on identifying targetable drivers associated with acquired chemoresistance. Particularly, AXL, a key receptor tyrosine kinase that confers resistance against targets and chemotherapeutics, is highly expressed in mesenchymal cancer cells. However, the underlying mechanism of AXL induction in mesenchymal cancer cells is poorly understood. Our study revealed that the YAP signature, which was highly enriched in mesenchymal‐type lung cancer, was closely correlated to AXL expression in 181 lung cancer cell lines. Moreover, using isogenic lung cancer cell pairs, we also found that doxorubicin treatment induced YAP nuclear translocation in mesenchymal‐type lung cancer cells to induce AXL expression. Additionally, the concurrent activation of TGFβ signaling coordinated YAP‐dependent AXL expression through SMAD4. These data suggest that crosstalk between YAP and the TGFβ/SMAD axis upon treatment with chemotherapeutics might be a promising target to improve chemosensitivity in mesenchymal‐type lung cancer.
Abbreviations
- AUC
- area under the curve
- AXL
- AXL receptor tyrosine kinase
- BCL2
- B‐cell lymphoma 2
- CTD2
- cancer target discovery and development
- CTGF
- connective tissue growth factor
- DEG
- differentially expressed genes
- DOXO
- doxorubicin
- EMT
- epithelial–mesenchymal transition
- Eto
- etoposide
- FDA
- Food and Drug Administration
- ITGB3
- integrin beta‐3
- MAPK
- mitogen‐activated protein kinase
- MMP2
- matrix metalloproteinase‐2
- MMP9
- matrix metalloproteinase‐9
- mRNA
- messenger RNA
- NF‐κB
- nuclear factor kappa‐light‐chain‐enhancer of activated B cells
- SBE
- SMAD binding element
- SERPINE1
- serpin family E member 1
- siRNA
- small interfering RNA
- ssGSEA
- single‐sample gene set enrichment analysis
- TCGA
- The Cancer Genome Atlas
- TGFβ
- transforming growth factor beta
- YAP
- Yes‐associated protein
- YAP8SA
- mutants of inhibitory phosphorylation site at eight serine to Alanine of YAP
- ZEB1
- zinc finger E‐box binding homeobox 1
- ZEB2
- zinc finger E‐box‐binding homeobox 2
34.
《Journal of vascular surgery》2020,71(6):1921-1929
ObjectiveIdentifying biomarkers for abdominal aortic aneurysms (AAA) could prove beneficial in prognosis of AAA and thus the selection for treatment. Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein that is highly expressed in aorta. MFAP4 is involved in several tissue remodeling-related diseases. We aimed to investigate the potential role of plasma MFAP4 (pMFAP4) as a biomarker of AAA.MethodsPlasma samples and data were obtained for 504 male AAA patients and 188 controls in the Viborg Vascular (VIVA) screening trial. The pMFAP4 levels were measured by Alphalisa. The Mann-Whitney U test assessed differences in pMFAP4 levels between the presence and absence of different exposures of interest. The correlation between pMFAP4 and aorta growth rate were investigated through spearman's correlation analysis. Immunohistochemistry and multiple logistic regression adjusted for potential confounders assessed the association between pMFAP4 and AAA. Multiple linear regression assessed the correlation between pMFAP4 and aorta growth rate. Cox regression and competing risk regression were used to investigate the correlation between AAA patients with upper tertile pMFAP4 and the risk of undergoing later surgical repair.ResultsA significant negative correlation between pMFAP4 and aorta growth rate was observed using spearman's correlation analysis (ρ = −0.14; P = .0074). However, this finding did not reach significance when applying multiple linear regression. A tendency of decreased pMFAP4 was observed in AAA using immunohistochemistry. Competing risk regression adjusted for potential confounders indicated that patients with upper tertile pMFAP4 had a hazard ratio of 0.51 (P = .001) for risk of undergoing later surgical repair.ConclusionsHigh levels of pMFAP4 are associated with a decreased likelihood of receiving surgical repair in AAA. This observation warrants confirmation in an independent cohort. 相似文献
35.
36.
37.
38.
A growing body of data suggests that therapies based on Toll-like receptors (TLR) targeting, in particular TLR4, holds promise in curing autoimmune and inflammatory pathologies still lacking specific treatment, included several rare diseases. While TLR4 activators (agonists) have already found successful clinical application as vaccine adjuvants, the use of TLR4 blockers (antagonists) as antisepsis agents or as agents against inflammatory diseases (including arthritis, multiple sclerosis, neuroinflammations) and cancer is still at a preclinical phase of development. This minireview focuses on recent achievements on the development of TLR4 modulators based on lipid A structure simplification, in particular on compounds having disaccharide or monosaccharide structures. As the TLR4 activity of natural TLR4 ligands (lipopolysaccharide, LPS and its biologically active part, the lipid A) depends on both the structure of endotoxin aggregates in solution and on single-molecule interaction with MD-2 and CD14 receptors, the rational design of TLR4 modulators should in principle take into account both these factors. In the light of the most recent advances in the field, in this minireview we discuss the structure–activity relationship in simplified lipid A analogs, with cationic or anionic amphiphilic structures. 相似文献
39.
40.